Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.1% in the afternoon session after the company reported positive Phase 3 data for retatrutide, its next-generation triple-agonist obesity drug.
The pharma giant is well-positioned to lead the $200 billion global obesity treatment market.
Infectious disease could fuel Eli Lilly's next growth phase.
Lilly’s Foundayo outperformed existing treatments on blood sugar control and weight loss in type 2 diabetes patients in three late-stage trials.
Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index shedding 0.4% and
New ATTAIN trial data shows up to 30.4 lbs lost across perimenopause and post-menopause groups
New obesity drug results could strengthen Lilly's lead in weight-loss treatments.
Eli Lilly (LLY) investors have been struggling to answer a deceptively straightforward question for the last two years. How big can the obesity medicine business get? The answer has already helped produce one of the most powerful growth stories in health care. Lilly’s blockbuster drugs Mounjaro and ...
Eli Lilly emerged as the "clear winner" from the ADA meeting last weekend in New Orleans, an analyst said following the event.
Novo's CEO says semaglutide could push the company beyond obesity and diabetes into longevity and appearance-related medicine.
Zealand Pharma's stock is cratering today after disappointing results from a late-stage trial of its GLP-1 dual-receptor agonist drug.
ABBV climbs 12% a month as investors weigh the raised 2026 guidance, Skyrizi and Rinvoq growth, and multiple pipeline updates.
Altimmune's dual-agonist pemvidutide faces key 2026 tests in MASH and alcohol-related diseases that could validate its multi-pathway liver strategy.
Altimmune is betting on pemvidutide across MASH and alcohol-related liver diseases, with key 2026 data and a planned Phase III launch shaping its path.
ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set to test pemvidutide's multi-indication story.
Roche collaborates with Nurix on bexobrutideg, a BTK degrader for blood cancers, while expanding potential use into immunology and neurology.
On this episode of Stock Movers with Alexis Christoforous: - Shares of The Campbell's Company (CPB) edged higher ahead of the US market open after the canned soup maker reported adjusted earnings per share for the third quarter that beat the average analyst estimate. - Eli Lilly (LLY) shares gained in the early session following obesity drug presentations at the American Diabetes Association conference. Citi analysts say their conviction on Lilly is firmly intact, given the company's incretin portfolio is "not built around singular blockbusters." - Shares of Marvell Technology (MRVL) and Flex (FLEX) are rising in premarket trading as the companies are set to replace Pool Corp. and Campbell's in S&P 500 before the market open on June 22, S&P Dow Jones Indices says in emailed statement.
Popping onto the IBD Leaderboard and two exclusive screens, Eli Lilly stock has returned to buy range after a brief hiccup.
Health care's seasonal strength and defensive appeal are in focus, with Eli Lilly's growth and Merck's pipeline progress highlighted as key drivers.
NVO says real-world data show Ozempic 2 mg matches Eli Lilly's Mounjaro on glucose control and is linked to a higher likelihood of meaningful weight loss.
NVO's oral Wegovy launch is off to a blistering start, topping 3 million prescriptions in five months and drawing many first-time GLP-1 users.
Eli Lilly (LLY) shares were up more than 2% pre-bell Monday after the company reported Saturday addi
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
